Global /United States /Healthcare /Biotechnology /MXCT
chevron_leftBack
MaxCyte, Inc. logo

MaxCyte, Inc.

MXCT
NASDAQ: MXCT Delayed
0.8176USD -6.8%
As of 13 June 2026, MaxCyte, Inc. has a market cap of $87.74M USD, ranking #26470 globally and #4040 in the United States. It ranks #2366 in the Healthcare sector, and #456 in the Biotechnology industry.
Global Rank
26470
Country Rank
4040
Sector Rank
2366
Industry Rank
456
Key Stats
Market Cap
$87.74MUSD
Enterprise Value
$2.64MUSD
Revenue (TTM)
$33.03MUSD
EBITDA (TTM)
-$40.22MUSD
Net Income (TTM)
-$44.63MUSD
EBITDA Margin
-122%
Profit Margin
-135%
PS Ratio
2.7
PB Ratio
0.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Maher Masoud open_in_new
Employees
91
Founded
1999
IPO
30 Jul 2021
Website
maxcyte.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-6.8% -5.7% 20% -19% -47% -72%

News

Loading...

MXCT Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
MXCT
MaxCyte Inc
ISIN: US57777K1060
Shares Out.:
107.122M1 Shares Float: 99.132M2
TV:
SA:
YF:
GF:
NQ:
BA:
MS:
0.8176 USD
London Stock Exchange
MIC: XLON
MXCT
MaxCyte Inc
ISIN: US57777K1060
Shares Out.:
106.319M1 Shares Float: 97.943M2
TV:
SA:
YF:
GF:
BA:
MS:
148 GBX
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Similar Companies

Industry: Biotechnology (United States)
Name
Market Cap diff.
PE
AMGN
$182.42B
208K%
23.9
GILD
$159.92B
182K%
19.0
NTRA
$27.6B
31K%
-
$26.3B
30K%
20.0
$25.03B
28K%
20.4
MRNA
$18.13B
21K%
-
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
ARGX
$47.84B
41.39B EUR
54K%
39.9
$44.84B
68.19T KRW
51K%
35.5
CSL
$42.36B
60.27B AUD
48K%
29.3
LONN
$42.3B
33.71B CHF
48K%
37.2
068270
$28.11B
42.76T KRW
32K%
43.8
BNTX
$25.69B
29K%
-
chevron_leftBack